RVMDW Financials: Revolution Medicines, Inc. AI Analysis

Breakdown	TTM	12/31/2025	12/31/2024	12/31/2023	12/31/2022	12/31/2021
Revenue	9,434	9,434	8,406	7,022	6,505	5,739
Revenue Growth (YoY)	12%	12%	20%	8%	13%	16%
Cost of Revenue	4,326	4,326	3,505	2,428	2,312	1,890
Gross Profit	5,108	5,108	4,901	4,594	4,193	3,849
Selling, General & Admin	2,600	2,600	2,565	2,451	2,155	1,923
Research & Development	--	--	--	--	--	--
Operating Expenses	2,610	2,610	2,574	2,469	2,194	1,943
Other Non Operating Income (Expenses)	--	--	--	--	--	--
Pretax Income	1,684	1,684	1,809	1,453	1,365	1,363
Income Tax Expense	483	483	364	-265	-117	110
Net Income	776	776	1,021	1,190	1,008	838
Net Income Growth	-24%	-24%	-14%	18%	20%	72%
Shares Outstanding (Diluted)	460	457	454	456	455	464
Shares Change (YoY)	1%	1%	0%	0%	-2%	-1%
EPS (Diluted)	1.68	1.69	2.24	2.6	2.21	1.8
EPS Growth	-25%	-25%	-14%	18%	23%	75%
Free Cash Flow	1,302	1,302	1,302	1,203	1,390	1,620
Free Cash Flow Per Share	--	--	--	--	--	--
Gross Margin	54.14%	54.14%	58.3%	65.42%	64.45%	67.06%
Operating Margin	26.47%	26.47%	27.68%	30.26%	30.73%	33.21%
Profit Margin	8.22%	8.22%	12.14%	16.94%	15.49%	14.6%
Free Cash Flow Margin	13.8%	13.8%	15.48%	17.13%	21.36%	28.22%
EBITDA	2,799	2,799	2,591	2,316	2,189	2,107
EBITDA Margin	29.66%	29.66%	30.82%	32.98%	33.65%	36.71%
D&A For EBITDA	301	301	264	191	190	201
EBIT	2,498	2,498	2,327	2,125	1,999	1,906
EBIT Margin	26.47%	26.47%	27.68%	30.26%	30.73%	33.21%
Effective Tax Rate	28.68%	28.68%	20.12%	-18.23%	-8.57%	8.07%

Revolution Medicines, Inc. (RVMDW) Financial